Connect with us


How Did Pfizer Grow With Weak Dollar?



How Did Pfizer Grow With Weak Dollar?
How was Pfizer helped by the weakening of dollar?

Pfizer topped the expectations when the pharmaceuticals giant on the first-quarter revenue went up to $13 billion with adjusted earnings per share of 67 cents. Not only this, Pfizer also shoots with a full-year guidance not only the top but both the top and bottom lines. Today, it is not expected on 2016 revenue to have $52 billion at the midpoint of guidance, up from $50 billion.

What helped this to happen? – The new products such as breast-cancer drug called Ibrance and the vaccine for pneumonia called Prevnar 13 is selling exceeding the anticipation of analysts. On the other hand, greenback’s recent travails also contributed to this help.

According to the Wall Street Journal Dollar Index, the measure of currency’s strength is up more than 25% over the last five years but also 6% down so far this year. The dollar is accounted for the half of Pfizer’s growth in the mid of its guidance.


Read more here…

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © 2023 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.


Is THE newsletter for…


Stay up-to-date with the latest kick-ass interviews, podcasts, and more as we cover a wide range of topics, in the world of finance and technology. Don't miss out on our exclusive content featuring expert opinions and market insights delivered to your inbox 100% FREE!